Polynucleotide therapy

Details Polynucleotide therapy Polynucleotide therapy

2002-11-21

2009-06-09

Kaushal, Sumesh (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S320100, C435S325000, C435S455000, C424S093100, C424S093200

Reexamination Certificate

active

07544669

ABSTRACT:
This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector. The invention also provides a composition comprising a polynucleotide encoding one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present non-physiologically in a treated animal useful in treating or preventing a disease associated with the self-protein(s), -polypeptide(s), or -peptide(s) present in and/or the target of a non-physiologic process in the animal.

REFERENCES:
patent: 5939400 (1999-08-01), Steinman et al.
patent: 6884785 (2005-04-01), von Herrath
patent: 7030098 (2006-04-01), Steinman et al.
patent: WO 86/01540 (1986-03-01), None
patent: WO 97/45144 (1997-12-01), None
patent: WO 97 45144 (1997-12-01), None
patent: WO 97 46253 (1997-12-01), None
patent: WO 00/53019 (2000-09-01), None
patent: WO 00/78360 (2000-12-01), None
Qing-Wen et al Zhongguo Mianyixue Zazhi 17(9): 478-481, 2001.
Chernavosky et al., Genes and Immunity 1:295-307, 2001.
von Herrath Nature, 435(7039):151-2.2005.
Chen et al JI 167:4926-4935, 2001.
Goncalves, Bioessays. 27(5):506-517, 2005.
Uengst, BMJ, 326:1410-11, 2003.
Check Nature 422:7, 2003.
Couzin et al, Science 307:1028, 2005.
Rosenberg et al, Science 287:1751, 2000.
Touchette, Nat. Med. 2(1) 7-8, 1996.
Solvason et al, J Immunol. 81(12):8298-307, 2008.
Steinman, Science. 305(5681):212-6, 2004.
Irene Urbanek-Ruiz, et al.; Immunization with DNA Encoding an Immunodominat Peptide of Insulin Prevents Diabetes in NOD Mic; Clinical Immunology; Journal, August, 164-171,vol. 100, No. 2, Aug. 2001; Academic Press; USA.
Pedro J. Ruiz, et al. Suppressive Immunization with DNA Encoding a Self-Peptide Prevents Autoimmune Disease: Modulation of T Cell Costimulation; The Journal of Immunology, Mar. 15, 1999, 162: 3336-3341, USA.
Prud 'Homme Gerald J., et al; Immunoinhibitory DNA Vaccine Protects Against Autoimmune Diabetes Through cDNA Encoding A Selective CTLA-4 (CD152) Ligand; Human Gene Therapy, Feb. 10, 2002, 395-406, v 13, No. 3; McGill University, Canada.
Jindal et al., Prevention of Diabetes in the NOD Mouse by Intra-Muscular Injection of Recombinant Adeno-Associated Virus Containing the Preproinsulin II Gene, International Journal of Experimental Diabetes Research, 2001, 2; 129-138.
Rapoport et al., Interleukin 4 Reverses T Cell Proliferative Unresponsiveness and Prevents the Onset of Diabetes in Nonobese Diabetic Mice, J Exp Med, 1993, 178; 87-99.
Wicker et al., Naturally Processed T Cell Epitopes From Human Glutamic Acid Decarboxylase Identified Using Mice Transgenic for the Type 1 Diabetes-Associated Human MHC Class II Allele, DRB1*0401, J Clin Invest, 1996, 98(11); 2597-2603.
Anderton et al., Hierarchy in the Ability of T Cell Epitopes to Induce Peripheral Tolerance to Antigens from Myelin, European Journal of Immunology, (1998), vol. 28:1251-1261.
Barnett et al., Virus Encoding an Encephalitogenic Peptide Protects Mice from Experimental Allergic Encephalomyelitis, Journal of Neuroimmunology, vol. 64:163-173.
Bebo et al., Male SJL Mice do not Relapse After Induction of EAE With PLP 139-151, Journal of Neuroscience Research, vol. 45:680-689.
Brocke, S. et al., Treatment of Experimental Encephalomyelitis with a Peptide Analogue of Myelin Basic Protein, Nature, (1996), 379, 343-6.
Bu Df et al., Two Human Glutamate Decarboxylases, 65-KDA GAD and 67-KDA GAD, are Each Encoded by a Single Gene, Proc Natl Acad Sci, (1992) USA 89(6): 2115-2119.
Cohen, et al., Exploring the Potential of DNA Vaccination, Hosp. Practice, (1997), pp. 169-177.
Coon et al., DNA Immunization to Prevent Autoimmune Diabetes,J. Clin. Invest, (1999), 104(2):189-94.
Davis, et al., DNA-Based Immunization Induces Continuous Secretion of Hepatitis B Surface Antigen and High Levels of Circulating Antibody, Human Mol. Genetics, (1993), V.11, pp. 1847-1851.
Davis, et al., Direct Gene Transfer in Skeletal Muscle: Plasmid DNA-Based Immunization Against the Hepatitis B Virus Surface Antigen, Vaccine, (1994), V. 12, No. 16, pp. 1503-1509.
Falo, et al., Giving DNA Vaccines a Helping Hand, Nature Medicine, V. 4, No. 11, (1998), pp. 1239-1240.
Garren, H. et al., Combination of Gene Delivery and DNA Vaccination to Protect From and Reverse TH1 Autoimmune Disease Via Deviation to the TH2 Pathway, Immunity, (2001), 15, 15-22.
Greer et al., Identification and Characterization of a Second Encephalitogenic Determinant of Myelin Proteolipid Protein (Residues 178-191) for SJL Mice, J. of Immunology, V. 149, (1992), pp. 783-788.
IFNB—MS—Study—Group, Interferon Beta-1B in the Treatment of Multiple Sclerosis: Final Outcome of the Randomized Controlled Trial, The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, (1995), Neurology 45, 1277-85.
Jacobs, Lawrence et al., Extended Observations on MS Patients Treated With IM Interfereon-β LA (Avonex™): Implications for Modern MS Trials and Therapeutics Presented in Part at Pathogenic and Regulatory Cells in Demyelinating Diseases, Rome, Italy, Sep. 12-15, 1999, Journal of Neuroimmunology, (2000), vol. 107, pp. 167-173.
Johnson, K. P et al., R. B. Copolymer 1 Reduces Relapse Rate and Improves Disability in Relapsing- Remitting Multiple Sclerosis: Results of a Phase III Multicenter, Double-Blind Placebo-Controlled Trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, (1995), 45, 1268-76.
Kamholz J et al., Identification of Three Forms of Human Myelin Basic Protein by CDNA Cloning, 1986, Proc Natl Acad Sci USA, 83:4962-6.
Kappos et al., Induction of a Non-Encephalitogenic Type 2 T Helper-Cell Autoimmune Response in Multiple Sclerosis After Administration of an Altered Peptide Ligand in a Placebo-Controlled, Randomized Phase II Trial, The Altered Peptide Ligand in Relapsing MS Study Group, (2000), Nat Med 6, 1176-82.
Karin, N. et al., Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon Gamma and Tumor Necrosis Factor Alpha Production, (1994), J Exp Med 180, 2227-37.
Kerlero de Rosbo, et al., T-Cell Responses T Myelin Antigens in Multiple Sclerosis; Relevance of the Predominant Autoimmune Reactivity to Myelin Oligodendrocyte Glycoprotein, J. of Autoimmunity, (1998), V. 11, pp. 287-299.
King et al., DNA Vaccines With Single-Chain FV Fused to Fragment C of Tetanus Toxin Induce Protective Immunity Against Lymphoma and Myeloma, Nature Medicine, V. 4, No. 11, (1998), pp. 1281-1286.
Krieg et al., The Role of CPG Dinucleotides in DNA Vaccines, Trends in Microbiology, V. 6, No. 1, (1998), pp. 23-27.
Le et al., Safety, Tolerability and Humoral Immune Responses After Intramuscular Administration of a Malaria DNA Vaccine to Healthy Adult Volunteers, Vaccine 18, (2000), 1893-901.
Leadbetter et al., Experimental Autoimmune Encephalomyelitis Induced With a Combination of Myelin Basic Protein and Myelin Oligodendrocyte Glycoprotein is Ameliorated by Administration of a Single Myelin Basic Protein Peptide, J. of Immunology, (1998), 161, pp. 504-512.
Ledley, FD., Pharmaceutical Approach to Somatic Gene Therapy, Pharmaceutical Research, vol. 13:1595-1613.
Liblau RS et al., TH1 and TH2 CD4+ T Cells in the Pathogenesis of Organ-Specific Autoimmune Diseases, Immunol Today, (1995), Jan;16(1):34-8.
Lisak, R. P. et al., Effect of Treatment With Copolymer 1 (COP-1) on the In Vivo and In Vitro Manifestations of Experimental Allergic Encephalomyelitis, (EAE), J Neurol Sci, (1983), 62: 281-93.
Lobell, A. et al., Presence of

Affiliated with

Also associated with

Rating

Polynucleotide therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polynucleotide therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotide therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4107519